RxDoctor Payments Data

Stephen Thomas, NP

Nurse Practitioner · Temecula, CANPI 1326584095

Payments from drug & device makers

$13,193in general payments, 2019–2025

Across 173 payments — averaging $76.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$8K
  • Akebia Therapeutics Inc$2K
  • Amgen$1K
  • Ardelyx, Inc.$706
  • Fresenius USA Marketing, Inc.$585
  • AstraZeneca$267
  • plus $551 from 10 others

What the payments were for

  • Consulting fees$3753%
  • Speaking & faculty fees$4,63535%
  • Travel & lodging$1,90614%
  • Food & beverage$6,27848%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,193 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$7,667
Medicare patients
28
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide30$101,344
VeltassaPatiromer Calcium Sorbitex49$82,831
XphozahTenapanor Hcl25$67,057
AuryxiaFerric Citrate20$55,355
Sevelamer Carbonate115$48,781
ClinolipidFat Emulsion/Olive/Soy/Phospho127$34,308
ProsolParenteral Amino Acid 20% No.1153$29,064
Lanthanum Carbonate25$21,003
EliquisApixaban20$15,607
OzempicSemaglutide14$15,483
Calcium Acetate97$13,606
ClinisolParenteral Amino Acid 15% No.567$10,776
Midodrine Hcl30$3,646
Ondansetron OdtOndansetron17$1,767
Nifedipine ErNifedipine42$1,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$585$101,34430 claims
Akebia Therapeutics IncAuryxia$1,601$55,35520 claims
Novo NordiskOzempic$40$15,48314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →